Andrew Blitzer

Andrew Blitzer

Auto-generated profile, based on publicly available information

Andrew Blitzer

New York Center for Voice and Swallowing Disorders St. Luke's Roosevelt Medical Center New York New York U.S.A.

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1997 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
ABAndrew Blitzer
Andrew Blitzer
WBWilliam J. Binder
William J. Binder
JAJonathan E. Aviv
Jonathan E. Aviv
MKMonte S. Keen
Monte S. Keen
MBMitchell F. Brin
Mitchell F. Brin
Objective To determine the optimum dose and efficacy of botulinum toxin injections in the management of hyperfunctional facial lines. Design This study included 210 hyperfunctional facial sites in 162 different patients. The patients had preinjection and postinjection photographic documentation and ratings on a 4-point qualitative evaluation scale of lines at rest and with action. The patients then had botulinum toxin type A injections via a monopolar hollow bore, Teflon-coated electromyographic needle into the facial muscles associated with the hyperfunctional lines. The total dose for each region of 1.25 to 25 U was divided into 1.25- to 5-U aliquots representing 0.1 to 0.2 mL per injection site, depending on the site and the prior experience with that patient on using toxin. The patients had their reevaluation at 2 to 3 weeks after injection. Patients returned for further follow-up when the therapeutic effect diminished. Patients One hundred sixty-two patients had 210 hyperfunctional sites evaluated and injected. The group consisted of 25 male patients and 137 female patients ranging in age from 21 to 78 years with a mean (±SD) of 46.1 (±1.98) years. All patients had cosmetically troubling hyperfunctional lines involving the forehead, glabella, crow's feet (lateral canthal lines), nasolabial area, platysma, and mentalis region. Results All patients had an effect of toxin within the first 24 to 72 hours. Ninety-five percent of the patients treated had cosmetic improvement of unsightly facial lines or contractions. The best results were achieved in management of the forehead lines, followed by glabella, crow's feet, and nasolabial. The dose for forehead lines was 5 to 25 U (mean±SD, 17.3±6.2 U); glabellar lines, 5 to 20 U (mean±SD, 11.1±3.1 U); crow's feet, 5 to 15 U (mean±SD, 6.2±1.6 U); nasolabial, 2.5 to 5 U (mean±SD, 3.12±1.2 U); and platysma, 10 to 20 (mean±SD, 15±4.0 U). Evaluation by age and site suggested a trend of increased toxin dose with increased age. Effects of the toxin are usually seen 24 to 72 hours after injection, and last from 3 to 6 months, whereon the increased muscular activity returns, as do the hyperfunctional lines. The only morbidity was related to temporary mild weakness of other adjacent facial muscles. There were no systemic side effects noted. Conclusion Botulinum toxin is a safe and important adjunctive technique for the management of patients with symptomatic hyperfunctional facial lines.

8 December 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
ABAndrew Blitzer
Andrew Blitzer
MBMitchell F. Brin
Mitchell F. Brin
KSKristina Simonyan
Kristina Simonyan
LOLaurie J. Ozelius
Laurie J. Ozelius
SFSteven J. Frucht
Steven J. Frucht

18 April 2007 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
PSPc Song
Pc Song
JSJ Schwartz
J Schwartz
ABA Blitzer
A Blitzer

1 April 2013 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
LGLowell E. Gurey
Lowell E. Gurey
CSCatherine F. Sinclair
Catherine F. Sinclair
ABAndrew Blitzer
Andrew Blitzer

24 July 2015 in Toxins
Verified
Journal Article
Open access
PDF file
NMNiv Mor
Niv Mor
CTChristropher Tang
Christropher Tang
ABAndrew Blitzer
Andrew Blitzer
This article reviews the diagnoses and treatment of temporomandibular disorders (TMD) and outlines of the role of botulinum toxin (BoNT) in the treatment of myofacial TMD. This manuscript includes a brief history of the use of BoNT in the treatment of pain, the mechanism of action of BoNT, and the techniques for injections, adverse effects and contraindications when using BoNT to treat mayofacial pain caused by TMD.

5 October 2013 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
CSCatherine F. Sinclair
Catherine F. Sinclair
LGLowell E. Gurey
Lowell E. Gurey
ABAndrew Blitzer
Andrew Blitzer